Stay updated with breaking news from Slate Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI...
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cookiesI agree Cookie Settings Cookie Settings This website uses cookies to improve your experience whil...